
CLAIMS

1. A compound of Formula Ic:



or the pharmaceutically acceptable salt thereof;

wherein:

Y is NR^1R^2;

R^1 is methyl;

R^2 is hydrogen;

R^3 is hydrogen;

R^7 is hydrogen, $C_{1\text{-}6}$alkyl, $C_{3\text{-}7}$cycloalkyl or aryl;

R^8 is hydrogen or $C_{1\text{-}6}$alkyl;

R^{9a} and R^{9b} are independently selected from hydrogen, $C_{1\text{-}6}$alkyl, or cycloalkyl;

R^{10} is hydrogen, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$haloalkyl, or $C_{3\text{-}7}$cycloalkyl; and

R^{11} is $C_{1\text{-}6}$alkyl, cycloalkyl, $C_{2\text{-}6}$alkynyl, $C_{2\text{-}6}$alkenyl, or acyl.

2. The compound of claim 1,

wherein:

R^7 is aryl;

R^8 is hydrogen or C_1-C_4alkyl;

R^{9a} is C_1-C_6alkyl;

R^{9b} is hydrogen; and

R^{10} is C_1-C_6alkyl.

3. The compound of claim 2, wherein R^7 is phenyl.

4. The compound of claim 2, wherein R^7 is napthyl.

5. The compound of any one of claims 1-4, wherein R^8 is hydrogen.

6. The compound of any one of claim 1-4, wherein R^8 is methyl.

7. The compound of claim 1, wherein R^{9a} and R^{9b} are both $C_{1\text{-}6}$alkyl.

8. The compound of claim 7, wherein R^{9a} and R^{9b} are methyl.

9. The compound of claim 1, wherein R^{9a} is methyl and R^{9b} is hydrogen.

10. The compound of any one of claim 1-9, wherein R^{10} is methyl, ethyl, or iso-propyl.

11. The compound of claim 10, wherein R^{10} is isopropyl.

12. The compound of any one of claims 1-11, wherein a deuterium is substituted for hydrogen at one or more locations on the molecule.

13. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1-12 in a pharmaceutically acceptable carrier to treat HCV in a host.

14. The pharmaceutical composition of claim 13, in an oral dosage form.

15. The pharmaceutical composition of claim 14, in a tablet.

16. The pharmaceutical composition of claim 14, in a capsule.

17. A compound of any one of claims 1-12, optionally in a pharmaceutically acceptable carrier, for use in the treatment of HCV in a host.

18. The compound of claim 17, wherein the compound is to be administered in combination with another anti-HCV agent.

19. The compound of claim 18, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

20. The compound of any one of claims 17-19, wherein the host is a human.


21. Use of a compound of any one of claims 1-12, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the treatment of HCV in a host.

22. The use of claim 21, wherein the medicament is to be administered in combination with another anti-HCV agent.

23. The use of claim 22, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.


24. The use of claim any one of claims 21-23, wherein the host is a human.

25. A compound of the formula:




or a pharmaceutically acceptable salt thereof.

26. The compound of claim 25 of the formula:




or a pharmaceutically acceptable salt thereof.

27. The compound of claim 25 of the formula:




or a pharmaceutically acceptable salt thereof.

28. A compound of the formula:




or a pharmaceutically acceptable salt thereof.

29. The compound of claim 28 of the formula:



or a pharmaceutically acceptable salt thereof.

30. The compound of claim 28 of the formula:



or a pharmaceutically acceptable salt thereof.

31. The compound of any one of claims 25-30, wherein a deuterium is substituted for hydrogen at one or more locations on the molecule.

32. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 25-31 in a pharmaceutically acceptable carrier to treat HCV in a host.

33. The pharmaceutical composition of claim 32, in an oral dosage form.

34. The pharmaceutical composition of claim 33, in a tablet.

35. The pharmaceutical composition of claim 33, in a capsule.

36. A compound of any one of claims 25-31, optionally in a pharmaceutically acceptable carrier, for use in the treatment of HCV in a host.

37. The compound of claim 36, wherein the compound is to be administered in combination with another anti-HCV agent.

38. The compound of claim 37, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

39. The compound of any one of claims 36-38 and 44, wherein the host is a human.

40. Use of any one of claims 25-31, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the treatment of HCV in a host.

41. The use of claim 40, wherein the medicament is to be administered in combination with another anti-HCV agent.

42. The use of claim 41, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

43. The use of any one of claims 40-42 and 45, wherein the host is a human.

44. The compound of claim 38, wherein the additional anti-HCV agent is an NS5A inhibitor.

45. The use of claim 42, wherein the additional anti-HCV agent is an NS5A inhibitor.

46. The compound of claim 20 or 39, wherein the HCV is genotype 1a, 1b, 2a, 2b, 3a, 4a, or 4d.

47. The use of claim 24 or 43, wherein the HCV is genotype 1a, 1b, 2a, 2b, 3a, 4a, or 4d.